Join
Live feed
·
PRReleasevia Quantisnow
Jade Biosciences Inc. logo

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

ByQuantisnow·Wall Street's wire, on your screen.
JBIO· Jade Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JBIO (Jade Biosciences Inc.) and more on Quantisnow.